参考文献/References:
[1] Blumhardt R, Wolin EA, Phillips WT, et al.Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer:a narrative review[J].EndocrRelat Cancer, 2014, 21(6):R473-R484.DOI:10.1530/ERC-14-0286.
[2] 胡莹莹, 蒋宁一.131I治疗分化型甲状腺癌的现状和进展[J].国际放射医学核医学杂志, 2006, 30(6):343-346.DOI:10.3760/cma.j.issn.1673-4114.2006.06.007.Hu YY, Jiang NY.Radiodione treatment of differentiated thyroid cancer:current status and future prospects[J].Int J Radiat Med Nucl Med, 2006, 30(6):343-346.
[3] Zhang WD, Liu DR, Feng CC, et al.Management of differentiated thyroid carcinoma with bone metastasis:a case report and review of the Chinese literature[J].J Zhejiang Univ Sci B, 2014, 15(12):1081-1087.DOI:10.1631/jzus.B1400124.
[4] 张之南, 沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社, 2007:157.Zhang ZN, Shen D.The diagnostic and therapeutic effect of hemopathy[M].3th ed.Beijing:Science Press, 2007:157.
[5] 王卓颖, 吴毅.分化型甲状腺癌的诊治指南解读[J].外科理论与实践, 2014, 19(3):185-188.DOI:10.3969/j.issn.1007-9610.2014.03.001.Wang ZY, Wu Y.Interpretation of the Guide to the diagnosis and treatment of differentiated thyroid cancer[J].J Surg Concepts Pract, 2014, 19(3):185-188.
[6] 张桂芝, 谭建, 刘雪辉, 等.131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J].中华核医学杂志, 2010, 30(4):259-263.DOI:10.3760/cma.j.issn.0253-9780.2010.04.011.Zhang GZ, Tan J, Liu XH, et al.Influential factors on the effectiveness of 131I treatment on post-surgical differentiated thyroid cancer patients[J].Chin J Nucl Med, 2010, 30(4):259-263.
[7] 程辉, 余丹, 周静, 等.58例继发性骨髓增生异常综合征临床分析[C]//第八届全国中西医结合血液病学术会议论文集, 武汉, 2007:126-129.Cheng H, Yu D, Zhou J, et al.The clinical analysis of 58 cases with secondary myelodysplastic syndrome[C]//Proceedings of the eighth national academic conference on blood disease with traditional Chinese and Western medicine, Wuhan, 2007:126-129.
[8] 何广胜.骨髓增生异常综合征研究进展[J].中国实用内科杂志, 2014, 34(7):684-688.DOI:10.7504/nk2014060303.He GS.Research progress of myelodysplastic syndrome[J].Chin J Pract Intern Med, 2014, 34(7):684-688.
[9] 张朝霞, 王天有.骨髓增生异常综合征相关基因研究进展[J].中国小儿血液与肿瘤杂志, 2011, 16(2):89-92.DOI:10.3969/j.issn.1673-5323.2011.02.012.Zhang CX, Wang TY.The research progress of myelodysplastic syndrome related genes[J].J China Pediatr Blood Cancer, 2011, 16(2):89-92.
[10] 安利, 江明.114例骨髓增生异常综合征的染色体核型与预后分析[J].中山大学学报:医学科学版, 2014, 35(4):575-578.An L, Jiang M.Karyotype and prognosis analysis of 114 cases of myelodysplastic syndrome[J].J SUN Yat-sen Univ(Med Sci), 2014, 35(4):575-578.
[11] Hall P, Boice JD Jr, Berg G, et al.Leukaemia incidence after iodine-131 exposure[J].Lancet, 1992, 340(8810):1-4.
[12] Zhu RS, Yu YL, Lu HK, et al.Clinincal study of 312 cases with metastatic differentiated thyroid cancer treated with large doses of 131I[J].Chin Med J(Engl), 2005, 118(5):425-428.
[13] Walter MA, Turtschi CP, Schindler C, et al.The dental safety profile of high-dose radioiodine therapy for thyroid cancer:long-term results of a longitudinal cohort study[J].J Nucl Med, 2007, 48(10):1620-1625.DOI:10.2967/jnumed.107.042192.
[14] Kloos RT, Duvuuri V, Jhiang SM, et al.Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma[J].J Clin Endocrinol Metab, 2002, 87(12):5817-5820.DOI:http://dx.doi.org/10.1210/jc.2002-020210.